BDX expands its Ypsomed partnership with a 5.5 mL Neopak XtraFlow syringe, targeting rising demand for large-volume ...

BD and Ypsomed will expand their collaboration through the development of a 5.5 ml version of BD’s Neopak XtraFlow glass ...

The new 5.5ml BD Neopak XtraFlow Syringe uses BD’s advanced technologies, including thinner cannulas.

– Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatment – “Today's approval reflects our ...

VYVGART, the first-in-class FcRn blocker, now offers three administration options, including self-injection with a prefilled syringe Self-injection provides gMG and CIDP patients with flexibility for ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...

Xolair, an anti-immunoglobulin E antibody, is indicated for the treatment of moderate to severe persistent asthma, chronic idiopathic urticaria, and nasal polyps. The Food and Drug Administration (FDA ...

Fresenius Kabi Glycopyrrolate Injection, USP 0.6 mg per 3 mL Simplist prefilled syringe may be administered prior to or concomitantly with Simplist Neostigmine Methylsulfate Injection, USP 3 mg per 3 ...

EAST HANOVER, N.J., April 12, 2021 /PRNewswire/ — Novartis today announced that the US Food and Drug Administration (FDA) approved the supplemental Biologics License Application for Xolair (R) ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that ...